Adaptive Biotechnologies (ADPT) Long-Term Investments (2019 - 2026)

Adaptive Biotechnologies has disclosed Long-Term Investments across 7 years of filings, most recently posting $18.9 million for Q1 2026.

• Long-Term Investments for Q1 2026 came in at $18.9 million, down 52.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $18.9 million (down 52.0% YoY), and the FY2025 annual result was $13.2 million, down 60.68% from the prior year.
• Long-Term Investments came in at $18.9 million for Q1 2026 at Adaptive Biotechnologies, up from $13.2 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $137.1 million in Q1 2022 to a low of $4.0 million in Q3 2025.
• The 4-year median for Long-Term Investments is $24.0 million (2024), against an average of $38.1 million.
• Peak annual rise in Long-Term Investments reached 346.79% in 2022, while the deepest fall reached 90.94% in 2022.
• Adaptive Biotechnologies' Long-Term Investments stood at $19.7 million in 2022, then surged by 70.88% to $33.7 million in 2024, then sank by 60.68% to $13.2 million in 2025, then jumped by 42.73% to $18.9 million in 2026.
• The last three Long-Term Investments figures came in at $18.9 million (Q1 2026), $13.2 million (Q4 2025), and $4.0 million (Q3 2025), per Business Quant data.